Journal of Neuro-Oncology

, Volume 86, Issue 2, pp 133–141

Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment

  • Yu Liang
  • Maximilian Diehn
  • Andrew W. Bollen
  • Mark A. Israel
  • Nalin Gupta
lab. Investigation-human/animal tissue

Abstract

Medulloblastoma is the most common malignant brain tumor of children, and more specific and effective therapeutic management needs to be developed to improve upon existing survival rates and to avoid side-effects from current treatment. Gain of chromosome seven is the most frequent chromosome copy number aberration in medulloblastoma, suggesting that overexpression of genes on chromosome seven might be important for the pathogenesis of medulloblastoma. We used microarrays to identify chromosome seven genes overexpressed in medulloblastoma specimens, and validated using data from published gene expression datasets. The gene encoding the alpha 2 subunit of type I collagen, COL1A2, was overexpressed in all three datasets. Immunohistochemistry of tumor tissues revealed type I collagen in the leptomeninges, and in the extracellular matrix surrounding blood vessels and medulloblastoma cells. Expression of both type I collagen and the β1 subunit of integrin, a subunit of a known type I collagen receptor, localized to the same area of medulloblastoma. Adherence of D283 medulloblastoma cells to type I collagen matrix in vitro depends on the β1 subunit of integrin. Because medulloblastoma is characteristic of high vascularity, and because inhibition of type I collagen synthesis has been shown to suppress angiogenesis and tumor growth, our data suggest that type I collagen might be a potential therapeutic target for treating medulloblastoma.

Keywords

Medulloblastoma Microarray Extracellular matrix Type I collagen Adhesion 

Supplementary material

References

  1. 1.
    Jemal A, Murray T, Samuels A (2003) Cancer Statistics. CA Cancer J Clin 53:5–26PubMedGoogle Scholar
  2. 2.
    Rutkowski S (2006) Current treatment approaches to early childhood medulloblastoma. Expert Rev Neurother 6(8):1211–1221PubMedCrossRefGoogle Scholar
  3. 3.
    Evans AE, Jenkin RD, Sposto R et al (1990) The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72(4):572–582PubMedCrossRefGoogle Scholar
  4. 4.
    Packer RJ, Sutton LN, Elterman R et al (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81(5):690–698PubMedGoogle Scholar
  5. 5.
    Zeltzer PM, Boyett JM, Finlay JL et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17(3):832–845PubMedGoogle Scholar
  6. 6.
    Marino S (2005) Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 11(1):17–22PubMedCrossRefGoogle Scholar
  7. 7.
    MacDonald TJ, Brown KM, LaFleur B et al (2001) Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29(2):143–152PubMedCrossRefGoogle Scholar
  8. 8.
    Dirks PB, Harris L, Hoffman HJ et al (1996) Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 29(1):75–84PubMedCrossRefGoogle Scholar
  9. 9.
    Albright AL, Wisoff JH, Zeltzer P et al (1995) Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children’s Cancer Group. Pediatr Neurosurg 22(1):1–7PubMedGoogle Scholar
  10. 10.
    Cohen BH, Zeltzer PM, Boyett JM et al (1995) Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. J Clin Oncol 13(7):1687–1696PubMedGoogle Scholar
  11. 11.
    Huber H, Eggert A, Janss AJ et al (2001) Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer 37(16):2064–2072PubMedCrossRefGoogle Scholar
  12. 12.
    Grotzer MA, Wiewrodt R, Janss AJ et al (2001) High microvessel density in primitive neuroectodermal brain tumors of childhood. Neuropediatrics 32(2):75–79PubMedCrossRefGoogle Scholar
  13. 13.
    Pomeroy SL, Tamayo P, Gaasenbeek M et al (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415(6870):436–442PubMedCrossRefGoogle Scholar
  14. 14.
    Russo C, Pellarin M, Tingby O et al (1999) Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 86(2):331–339PubMedCrossRefGoogle Scholar
  15. 15.
    Burnett ME, White EC, Sih S, von Haken MS, Cogen PH (1997) Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system. Cancer Genet Cytogenet 97(1):25–31PubMedCrossRefGoogle Scholar
  16. 16.
    McCabe MG, Ichimura K, Liu L et al (2006) High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 65(6):549–561PubMedGoogle Scholar
  17. 17.
    Bayani J, Zielenska M, Marrano P et al (2000) Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 93(3):437–448PubMedGoogle Scholar
  18. 18.
    Reardon DA, Michalkiewicz E, Boyett JM et al (1997) Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 57(18):4042–4047PubMedGoogle Scholar
  19. 19.
    Ramaswamy S, Tamayo P, Rifkin R et al (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 98(26):15149–15154PubMedCrossRefGoogle Scholar
  20. 20.
    Boon K, Osorio EC, Greenhut SF et al (2002) An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A 99(17):11287–11292PubMedCrossRefGoogle Scholar
  21. 21.
    Velculescu VE, Zhang L, Vogelstein B, Kinzler KW (1995) Serial analysis of gene expression. Science 270(5235):484–487PubMedCrossRefGoogle Scholar
  22. 22.
    Karsenty G, Park RW (1995) Regulation of type I collagen genes expression. Int Rev Immunol 12(2–4):177–185PubMedCrossRefGoogle Scholar
  23. 23.
    Karsenty G, de Crombrugghe B (1991) Conservation of binding sites for regulatory factors in the coordinately expressed alpha 1 (I) and alpha 2 (I) collagen promoters. Biochem Biophys Res Commun 177(1):538–544PubMedCrossRefGoogle Scholar
  24. 24.
    Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH (1989) Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 109(2):877–889PubMedCrossRefGoogle Scholar
  25. 25.
    Wayner EA, Gil SG, Murphy GF, Wilke MS, Carter WG (1993) Epiligrin, a component of epithelial basement membranes, is an adhesive ligand for alpha 3 beta 1 positive T lymphocytes. J Cell Biol 121(5):1141–1152PubMedCrossRefGoogle Scholar
  26. 26.
    Quackenbush J (2006) Microarray analysis and tumor classification. N Engl J Med 354(23):2463–2472PubMedCrossRefGoogle Scholar
  27. 27.
    Liang Y, Diehn M, Watson N et al (2005) Gene expression profiling reveals clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102(16):5814–5819PubMedCrossRefGoogle Scholar
  28. 28.
    Liang Y, Bollen AW, Nicholas MK, Gupta N (2005) Id4 and FABP7 are preferentially expressed in cells with astrocytic features in oligodendrogliomas and oligoastrocytomas. BMC Clin Pathol 5:6PubMedCrossRefGoogle Scholar
  29. 29.
    Liang Y, Bollen AW, Aldape KD, Gupta N (2006) Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 6:97PubMedCrossRefGoogle Scholar
  30. 30.
    Montesano R, Orci L, Vassalli P (1983) In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97(5 Pt 1):1648–1652PubMedCrossRefGoogle Scholar
  31. 31.
    Jackson CJ, Jenkins KL (1991) Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp Cell Res 192(1):319–323PubMedCrossRefGoogle Scholar
  32. 32.
    Elkin M, Miao HQ, Nagler A et al (2000) Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. Faseb J 14(15):2477–2485PubMedCrossRefGoogle Scholar
  33. 33.
    Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M (1999) Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1(4):321–329PubMedCrossRefGoogle Scholar
  34. 34.
    Elkin M, Ariel I, Miao HQ et al (1999) Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 59(16):4111–4118PubMedGoogle Scholar
  35. 35.
    Gross DJ, Reibstein I, Weiss L et al (2003) Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res 9(10 Pt 1):3788–3793PubMedGoogle Scholar
  36. 36.
    White DJ, Puranen S, Johnson MS, Heino J (2004) The collagen receptor subfamily of the integrins. Int J Biochem Cell Biol 36(8):1405–1410PubMedCrossRefGoogle Scholar
  37. 37.
    Gamble JR, Matthias LJ, Meyer G et al (1993) Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 121(4):931–943PubMedCrossRefGoogle Scholar
  38. 38.
    Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5(10):816–826PubMedCrossRefGoogle Scholar
  39. 39.
    Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L et al (1996) Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379(6560):91–96PubMedCrossRefGoogle Scholar
  40. 40.
    Wu C, Dedhar S (2001) Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 155(4):505–510PubMedCrossRefGoogle Scholar
  41. 41.
    MacDonald TJ, Taga T, Shimada H et al (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48(1):151–157PubMedCrossRefGoogle Scholar
  42. 42.
    Taga T, Suzuki A, Gonzalez-Gomez I et al (2002) alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98(5):690–697PubMedCrossRefGoogle Scholar
  43. 43.
    Rutka JT, Giblin J, Dougherty DV et al (1986) An ultrastructural and immunocytochemical analysis of leptomeningeal and meningioma cultures. J Neuropathol Exp Neurol 45(3):285–303PubMedCrossRefGoogle Scholar
  44. 44.
    Rutka JT (1997) Medulloblastoma. Clin Neurosurg 44:571–585PubMedGoogle Scholar
  45. 45.
    Ozer E, Sarialioglu F, Cetingoz R et al (2004) Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study. Pathol Res Pract 200(7–8):501–509PubMedCrossRefGoogle Scholar
  46. 46.
    Chung DH, Lee JI, Kook MC et al (1998) ILK (beta1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing’s sarcoma and primitive neuroectodermal tumour. Virchows Arch 433(2):113–117PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Yu Liang
    • 1
    • 2
  • Maximilian Diehn
    • 3
    • 4
  • Andrew W. Bollen
    • 5
  • Mark A. Israel
    • 6
  • Nalin Gupta
    • 1
  1. 1.Department of Neurological Surgery, Brain Tumor Research CenterUniversity of CaliforniaSan FranciscoUSA
  2. 2.Division of Molecular Cell BiologyApplied BiosystemsFoster CityUSA
  3. 3.Department of Radiation OncologyStanford University School of MedicineStanfordUSA
  4. 4.Department of BiochemistryStanford University School of MedicineStanfordUSA
  5. 5.Department of PathologyUniversity of CaliforniaSan FranciscoUSA
  6. 6.Departments of Pediatrics and GeneticsNorris Cotton Cancer Center, Dartmouth Medical SchoolLebanonUSA

Personalised recommendations